Nuwiq Demonstrates Low Inhibitor Development Rates In Previously Untreated Patients With Severe Hemophilia A
Lachen, Switzerland – Octapharma has announced that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe hemophilia A have been published in the medical journal…